Atea Pharmaceuticals
Update in progressAVIR (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on oral antiviral therapies for serious viral infections. Its lead regimen combines bemnifosbuvir, a nucleotide NS5B inhibitor, with ruzasvir, an NS5A inhibitor, in Phase 3 for hepatitis C. The company is also advancing AT-587 in Phase 1 for chronic HEV and offers a proprietary nucleoside platform for antiviral development. It licenses ruzasvir from MSD. Founded in 2012, Boston.
Company score
- Sentiment
- -0.07
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.14
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.01
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Jean-Pierre Sommadossi Ph.D.
- Founded2012
- Employees55
- Websiteateapharma.com
Identifiers
- ISINUS04683R1068
- FIGIBBG00TZNCJ75
- CUSIP04683R106
- CIK0001593899